| HOME >> BIOLOGY >> TECHNOLOGY |
CAMBRIDGE, Mass., June 24 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases, announced today that it has been named to the annual FierceBiotech "Fierce 15" list, designating it as one of the top biotech companies of 2008. The editors of FierceBiotech evaluated hundreds of privately-held firms based on company vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position. Tolerx was determined to be one of the "fiercest," proven by its creativity and innovations in the industry.
An internationally recognized daily newsletter reaching more than 65,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick authoritative briefing on the day's top stories, with a special focus on drug discovery and clinical trials.
John Carroll, Editor of FierceBiotech, said, "A rich partnership pact with GlaxoSmithKline last October kept Tolerx in the race to develop an anti-CD3 monoclonal antibody for autoimmune disease. That program has now begun a Phase III clinical trial known as DEFEND, and all the chips are on the table."
"FierceBiotech is renowned for its advanced understanding of biotechnology companies and the industry as a whole," said Dr. Douglas J. Ringler, President and Chief Executive Officer of Tolerx. "Being selected as a member of the 'Fierce 15' is an honor that highlights Tolerx's potential to make a significant impact in the biotech market."
The Fierce 15 celebrates the spirit of being "fierce" -- championing innovation and creativity, even in the face of intense competition. The complete list of 'Fierce 15' companies is available in today's issue of FierceBiotech and on the FierceBiotech Web site at http://www.fiercebiotech.com.
About Tolerx
Tolerx is a biopharma
'/>"/>
| SOURCE Tolerx, Inc. Copyright©2008 PR Newswire. All rights reserved |